Canadian professional groups recommended deprescribing proton pump inhibitors (PPIs) in adults who have completed a minimum of 4 weeks of PPI treatment for heartburn or mild to moderate gastroesophageal reflux disease or esophagitis, and whose symptoms are resolved. Deprescirbing by decreasing the daily dose or stopping and changing to on-demand (as needed) use of PPIs or considering histamine-2 receptor antagonist as an alternative to PPIs, after 4 weeks of treatment when symptoms have resolved. However, the recommendations do not apply to those who have or have had Barrett esophagus, severe esophagitis grade C or D, or documented history of bleeding gastrointestinal ulcers. There is growing concern about overuse of PPIs. Source: https://www.ti.ubc.ca/; http://www.cfp.ca/
A secondary MRI analysis of the US POINTER randomized clinical trial found that a structured…
Dementia risk factors vary substantially across countries, but they frequently cluster together in similar patterns…
A systematic review and network meta-analysis of 262 randomized trials involving 99,791 participants found that…
Approximately 21% of patients with phenotypically mild hypertrophic cardiomyopathy (HCM) experienced major adverse cardiovascular events…
A Danish randomized crossover trial found that a single session of high-intensity interval exercise (HIIE)…
Baseline use of proton pump inhibitors (PPIs) and, to a lesser extent, antibiotics was associated…
This website uses cookies.